crinecerfont
crinecerfont: sourced relationships with 1 company · 2 clinical trials tracked · 2 FDA decisions.
crinecerfont evidence translation
What we can confirm
2 FDA records · 2 tracked trials
What it means
What to watch
Prepared research question
How could crinecerfont → NBIX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Phase 3 |
Clinical Trial Registry Records (2)
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAE)
A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
Primary endpoint: Plasma Concentration of Crinecerfont
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with crinecerfont?
crinecerfont has dated SEC/FDA relationship records for NEUROCRINE BIOSCIENCES INC.
How many clinical trials involve crinecerfont?
BioSniper tracks 2 clinical trials involving crinecerfont.
What is crinecerfont's latest FDA decision?
The most recent tracked FDA decision for crinecerfont is Approval, dated December 13, 2024.